Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study

BACKGROUND: Second- or third-line treatment options for metastatic renal cell carcinoma (mRCC) have dramatically changed in the last few years. There are no criteria for the choice between nivolumab and cabozantinib, which both demonstrated overall survival (OS) gain in pivotal trials. OBJECTIVE: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruzzo, Marco, Pierantoni, Francesco, Bortolami, Alberto, Palleschi, Dario, Zivi, Andrea, Nicodemo, Maurizio, Sartori, Donata, De Vivo, Rocco, Zustovich, Fable, Bimbatti, Davide, Pastorelli, Davide, Vultaggio, Giuseppe Dione, Soraru’, Mariella, Ballestrin, Melissa, Modonesi, Caterina, Randisi, Paola, Barile, Carmen, Perri, Gino, Basso, Umberto, Zagonel, Vittorina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345814/
https://www.ncbi.nlm.nih.gov/pubmed/35751733
http://dx.doi.org/10.1007/s11523-022-00892-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345814/
https://www.ncbi.nlm.nih.gov/pubmed/35751733
http://dx.doi.org/10.1007/s11523-022-00892-z

Ejemplares similares